/EINPresswire.com/ -- IRVINE, CA--(Marketwired - Mar 30, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in cannabis formulation-based drug development, today announced that leader of global health information, Ms. Julia Royall, has been appointed to the Scientific Advisory Board of CBIS.

Ms. Royall is a Member of the Scientific Advisory Board. As a specialized consultant, she will provide advice and expertise on health information databases, management systems, and Internet technology. Julia Royall is a leader in health information and has been working in international health in Africa since 1990, with more than 40 years of professional experience in the communications field. Julia's commitment is to bring together information and technology with partners, projects and funding, using a variety of media.

Ms. Royall was recruited to the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in 1997 to create a malaria research communications network (MIMCom) to support scientists in Africa as part of the Multilateral Initiative on Malaria. The first network of its kind, MIMCom comprised 27 research sites in 14 African countries and engaged over 30 partner organizations and institutions in the US, UK, Europe, and Africa.

As Chief of NLM's Office of International Programs, she created innovative programs which focused on Africa and comprised outreach to medical librarians, medical journal editors, researchers, medical students, and health workers at the village level. In addition to adapting NLM databases for use in Africa, her work has encompassed a variety of media -- from web-based interactive digital tutorials to posters and video. Under Ms. Royall's leadership, NLM developed greater focus on global health by piloting demonstration projects which drew strength from one another and tied into NLM's major programs and databases.

Prior to government service, she was Deputy Director of SatelLife, a nonprofit dedicated to satellite delivery of public health and medical information in developing countries. As part of the team setting up the first Internet connections for health in sub Saharan Africa, she initiated and directed the HealthNet Information Service. HealthNet News was the first electronic health publication on the continent, published weekly for 20 years and pioneered digital sharing of medical literature in medical schools of sub Saharan Africa.

In 2007 - 2008, she was Fulbright Scholar to Uganda, based in the Office of the Dean at Makerere University, and has since served as a Fulbright Specialist at Kenyatta University in the Office of the Vice Chancellor.

Retired from U.S. Government service, she is currently principal investigator for the African Digital Health Library (ADHL), funded by the Office of Global AIDS Coordinator/U.S. Department of State. Based at 5 universities across Africa, ADHL will showcase in-country research previously not digitally accessible. She is also developing an African Student Innovation Fund with Carnegie Mellon University's Africa campus in Kigali, Rwanda.

www.juliaroyall.com

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3124499